Edwards Lifesciences Corp
EW75.090USD
-0.960-1.26%
Close 09/16, 16:00（ET）Quotes delayed by 15 min
44.15BMarket Cap
10.64P/E TTM
More Details of Edwards Lifesciences Corp Company
Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.
Company Info
Ticker SymbolEW
Company nameEdwards Lifesciences Corp
IPO dateMar 27, 2000
CEOMr. Bernard J. Zovighian
Number of employees15800
Security typeOrdinary Share
Fiscal year-endMar 27
AddressOne Edwards Way
CityIRVINE
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code92614
Phone19492502500
Websitehttps://www.edwards.com
Ticker SymbolEW
IPO dateMar 27, 2000
CEOMr. Bernard J. Zovighian
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
+3.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+6.56%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
+120.44%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
-17.30%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
19.91K
+19.18%
Mr. Paul A. Laviolette
Mr. Paul A. Laviolette
Independent Director
Independent Director
11.25K
+45.71%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.84K
+152.86%
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Mr. Donald E. Bobo, Jr.
Mr. Donald E. Bobo, Jr.
Corporate Vice President - Strategy and Corporate Development
Corporate Vice President - Strategy and Corporate Development
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
+3.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+6.56%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
+120.44%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
-17.30%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
19.91K
+19.18%
Mr. Paul A. Laviolette
Mr. Paul A. Laviolette
Independent Director
Independent Director
11.25K
+45.71%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
By BusinessUSD
Name
Revenue
Proportion
Transcatheter Aortic Valve Replacement
1.05B
74.09%
Surgical Heart Valve Therapy
250.90M
17.76%
Transcatheter Mitral and Tricuspid Therapies
115.20M
8.15%
By RegionUSD
Name
Revenue
Proportion
United States
838.90M
59.38%
Europe
341.80M
24.19%
Rest of the world
150.20M
10.63%
Japan
81.80M
5.79%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Transcatheter Aortic Valve Replacement
1.05B
74.09%
Surgical Heart Valve Therapy
250.90M
17.76%
Transcatheter Mitral and Tricuspid Therapies
115.20M
8.15%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.88%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Global Advisors (US)
4.37%
JP Morgan Asset Management
3.42%
Wellington Management Company, LLP
3.38%
Other
71.70%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.88%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Global Advisors (US)
4.37%
JP Morgan Asset Management
3.42%
Wellington Management Company, LLP
3.38%
Other
71.70%
Shareholder Types
Shareholders
Proportion
Investment Advisor
43.47%
Investment Advisor/Hedge Fund
29.29%
Hedge Fund
6.66%
Research Firm
2.13%
Pension Fund
2.13%
Bank and Trust
1.93%
Sovereign Wealth Fund
1.35%
Individual Investor
0.92%
Endowment Fund
0.82%
Other
11.29%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
2595
528.14M
89.95%
-20.66M
2025Q1
2628
535.29M
91.24%
-19.91M
2024Q4
2597
531.64M
90.42%
-4.10M
2024Q3
2568
511.38M
84.93%
-20.94M
2024Q2
2559
522.19M
86.68%
-12.58M
2024Q1
2572
518.82M
86.18%
-12.08M
2023Q4
2573
509.93M
84.08%
-27.42M
2023Q3
2530
522.96M
86.03%
-18.75M
2023Q2
2517
523.54M
86.35%
-20.02M
2023Q1
2495
522.98M
86.26%
-32.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
68.94M
11.75%
+70.46K
+0.10%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
32.28M
5.5%
+544.18K
+1.71%
Mar 31, 2025
State Street Global Advisors (US)
25.78M
4.4%
-25.16K
-0.10%
Mar 31, 2025
JP Morgan Asset Management
16.37M
2.79%
+5.61M
+52.12%
Mar 31, 2025
Wellington Management Company, LLP
29.13M
4.97%
-4.08M
-12.27%
Mar 31, 2025
Citadel Advisors LLC
13.38M
2.28%
+3.96M
+42.09%
Mar 31, 2025
Geode Capital Management, L.L.C.
12.68M
2.16%
-970.48K
-7.11%
Mar 31, 2025
Jennison Associates LLC
10.09M
1.72%
+2.58M
+34.31%
Mar 31, 2025
Walter Scott & Partners Ltd.
9.06M
1.54%
-347.38K
-3.69%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
iShares U.S. Medical Devices ETF
4.91%
Future Fund Long/Short ETF
3.53%
iShares Health Innovation Active ETF
3.33%
Hennessy Sustainable ETF
3.29%
Global X Aging Population ETF
3.19%
First Trust Indxx Medical Devices ETF
2.24%
SPDR S&P Health Care Equipment ETF
2.05%
Brown Advisory Flexible Equity ETF
1.99%
Tema Heart & Health ETF
1.93%
Invesco S&P 500 Equal Weight Health Care ETF
1.84%
View more
iShares U.S. Medical Devices ETF
Proportion4.91%
Future Fund Long/Short ETF
Proportion3.53%
iShares Health Innovation Active ETF
Proportion3.33%
Hennessy Sustainable ETF
Proportion3.29%
Global X Aging Population ETF
Proportion3.19%
First Trust Indxx Medical Devices ETF
Proportion2.24%
SPDR S&P Health Care Equipment ETF
Proportion2.05%
Brown Advisory Flexible Equity ETF
Proportion1.99%
Tema Heart & Health ETF
Proportion1.93%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.84%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 07, 2020
Split
1→3
Date
Type
Ratio
May 07, 2020
Split
1→3
